OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
OSCO’s recent presentation of the Official Review of the San Antonio Breast Cancer Symposium provided attendees with excellent updates on many breast cancer topics. The first session was presented by Joyce O’Shaughnessy, MD on HR+ Breast Cancer. The second session was a Radiation Oncology Update presented by Danushka Seneviratne, MD, PhD. After a short break […]
Read More...Pfizer Oncology is proud to announce the FDA approval of a new pediatric indication for BESPONSA® (inotuzumab ozogamicin). The following information is available for review: · Full Prescribing Information Including Boxed Warning
Read More...AstraZeneca’s TAGRISSO® (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval following a Priority Review by the Food and Drug Administration (FDA) was based on the results from the FLAURA2 Phase III trial […]
Read More...Join the Oklahoma Society of Clinical Oncology, Inc. for our Spring meeting on April 6, 2024, the Best of SABCS, an officially licensed program of the San Antonio Breast Cancer Symposium. This meeting will break down the most clinically relevant abstracts from SABCS’s annual symposium, allowing attendees to engage with the latest strategies in oncology education. Details of the in-person meeting are:
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at kmussonokc@gmail.com or by phone at 405-850-8334.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.
